secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001162194-23-000055
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q2 revenue up 47% to $27.7M; gross margins surge
------------------------------------------------------------------

- Revenue $27.7M (+47% YoY); GAAP gross margin 49.2% vs 23.6% YoY.
- Non-GAAP gross margin 60.9% vs 40.2%; operating loss improved to ($17.4M) from ($38.6M).
- Non-GAAP operating expenses down 25% to $25.2M; net loss ($17.0M) vs ($63.5M).
- Non-GAAP adjusted EBITDA loss ($8.4M) vs ($26.2M); operating cash use down >70% to $8.5M.
- Cash and equivalents $143.1M; launched Hyperion XTi Imaging System.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000116219423000055/0001162194-23-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000116219423000055/lab-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001162194-23-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer